Kent, United Kingdom

Susan Ann Taylor

This inventor holds 1 USPTO granted patent. Top assignee: The Wellcome Foundation Limited. Active years: 1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Susan Ann Taylor. Retrieved from https://idiyas.com/inventor/susan-ann-taylor

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Susan Ann Taylor

Introduction: Susan Ann Taylor is a notable inventor based in Kent, GB. She has made significant contributions to the field of pharmaceuticals, particularly with her work on lamotrigine. Her innovative approach has led to the development of a pharmaceutical composition that has the potential to impact many lives.

Latest Patents: Susan holds 1 patent for her invention related to a pharmaceutical composition of lamotrigine. This patent showcases her expertise and dedication to advancing medical science.

Career Highlights: Throughout her career, Susan has been associated with The Wellcome Foundation Limited, a prominent organization in the pharmaceutical industry. Her work there has allowed her to focus on groundbreaking research and development.

Collaborations: One of her notable collaborators is Simon Philip Hiskett. Together, they have worked on various projects that aim to enhance the efficacy of pharmaceutical treatments.

Conclusion: Susan Ann Taylor's contributions to the field of pharmaceuticals exemplify her commitment to innovation and improving healthcare solutions. Her work continues to inspire future generations of inventors and researchers.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…